Mocetinostat_726169-73-9_CoA_MedChemExpress

Endotoxin Removal Solution Catalog Number E4274Product DescriptionEndotoxins are lipopolysaccharides (LPS), a major component of the Gram-negative bacterial cell wall, and are commonly found as contaminants in plasmid DNA preparations from E. coli. Endotoxins are large, negatively charged molecules that co-purify with DNA on ion exchange and size exclusion columns and in CsCl banding. Endotoxins are extremely potent stimulators of the mammalian immune system and are toxic to primary cells and to animals. The endotoxin toxicity is an obstacle to in vitro and in vivo transfection experiments.Non-ionic detergents, traditionally used for separation of integral membrane proteins,1 can be utilized for removal of endotoxins from DNA solutions by phase separation.2The solubility behavior of a detergent in a dilute, aqueous solution at physiological salt and pH conditions is strongly dependent upon the temperature of the solution. At low temperatures, the detergent forms a clear, micellar solution, but above the cloud point temperature, the micelles form larger, turbid aggregates and ultimately fuse to form a separate phase. The lower phase is detergent-enriched and the detergent-depleted upper phase contains detergent at a concentration slightly above the critical micellar concentration (CMC). Amphiphilic and hydrophobic molecules associated with the micelles of the detergent will aggregate within the detergent-enriched phase, while the soluble, hydrophilic molecules will remain in the detergent-depleted upper phase.Extraction of endotoxin contaminated DNA solutions with the appropriate non-ionic detergent will separate the hydrophilic DNA from the amphiphilic endotoxin. The amphiphilic endotoxin will associate with the lower phase, while the DNA will remain in the upper, detergent-depleted phase.2Reagents and equipment required, but not provided • Water, Molecular Biology Reagent, Catalog Number W4502• E-TOXATE® Water, Catalog Number 2107, or Tris-EDTA (TE) buffer 100×, Catalog NumberT9285• DNA solution (0.5 ml), ~ 1 mg/ml in E-TOXATE®Water or TE buffer• 3 M sodium acetate solution, pH 7.5.• 2-Propanol, Catalog Number I9516, or Ethanol, 190 proof, Catalog Number E7148; 200 proof, CatalogNumber E7023• 70% Ethanol• E-TOXATE®reagents Kits, Catalog Numbers 210A1, 210B1 or 210C1• Ice bucket• Heat block or incubator at 37 °C• Microcentrifuge at room temperature• 1.5 or 2 ml sterile microcentrifuge tubes• Endotoxin-free pipet tips (40-200 µl, 200-1000 µl) Precautions and DisclaimerThis product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.StorageStore at room temperature.Note: Removal of endotoxins from DNA preparations can be performed either during the final stage of DNApreparation, or during an earlier stage.Procedures for Endotoxin RemovalDuring the final stage of DNA preparationNote: The procedure described below was performed on plasmid DNA produced in E. coli DH5α cells.• Losses of up to 50% of the DNA are expected. • Use of a DNA concentration above therecommended 1 mg/ml reduces the efficiency ofthe procedure.1. Pipette 500 µl of the DNA solution into a sterilemicrocentrifuge tube.2. Add 50 µl of the 3 M sodium acetate solution to theDNA sample.3. Incubate on ice for 5 minutes.4. Add 100 µl of cold Endotoxin Removal Solution.5. Mix thoroughly and incubate on ice for 10 minutes.The solution should be light blue and clear.6. Incubate the tube at 37 °C for 20 to 30 minutes oruntil the phases separate.7. Spin for 5 minutes at 3000 x g in themicrocentrifuge. The upper phase is colorless and clear, while the lower phase is blue.8. Carefully transfer the upper phase containing theDNA to a clean microcentrifuge tube.9. Repeat steps 4 through 8 twice.10. Add 0.6× volume of 2-propanol. Mix by inversion atroom temperature and centrifuge at 15,000 x g for30 minutes at 4 °C. Alternatively, add2.5× volumes of ethanol. Incubate overnight at –20°C or 20 minutes at –70 °C and centrifuge at15,000 x g for 30 minutes at 4 °C.11. Carefully remove the supernatant12. Wash the DNA pellet twice with cold 70% ethanol.Remove the supernatant.13. Air-dry the pellet.14. Suspend the DNA in 100 µl of endotoxin free wateror TE buffer.15. Determine DNA concentration and endotoxin levelsusing endotoxin assay reagents and compare tothe starting material. During an earlier stage of DNA preparationThis procedure is based on the alkaline lysis of E. coli DH5α cells.3 The endotoxins are removed immediately after alkaline cell lysis, neutralization, and a clarification step. The resulting high salt solution is suitable for the endotoxin removal step. It is performed under “endotoxin free” conditions. The plasticware used is either sterile and disposable, or NaOH-treated. The buffers are prepared with endotoxin free water.1. Add the Endotoxin Removal Solution (0.2× volume)to the cold, crude DNA solution.2. Incubate on ice and mix occasionally by inversionto obtain a homogenous, clear blue solution3. Incubate at 37 °C for 20 to 30 minutes until thephase separation is obvious.4. Spin for 5 minutes at low speed (3000 x g) at roomtemperature.5. Transfer the upper aqueous phase to an endotoxinfree container.6. Proceed with the DNA purification by any method.Use endotoxin-free buffers and containers. References1. Bordier, C., J. Biol. Chem., 256, 1604-1607, (1981).2. Cotten, M. et al., Gene Therapy, 1, 239-246,(1994).3. Sambrook et al., Molecular Cloning, a LaboratoryManual, 2nd Ed. p. 1.38RK,PHC 09/05-1Sigma brand products are sold through Sigma-Aldrich, Inc.Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side ofthe invoice or packing slip.。

Sutent药物基本信息〖NDA申请人〗CPPY CV〖NDA原始批准日期〗2006年07月26日〖剂型/规格〗胶囊剂/12.5mg；胶囊剂/25mg；胶囊剂/50mg；胶囊剂/37.5mg〖适应证〗50mg QD，用于治疗：Ⅰ、病情恶化后或对马来酸伊马替尼不耐受的胃肠间质瘤；Ⅱ、晚期肾细胞瘤活性成分信息〖USAN名称〗Sunitinib Malate，苹果酸舒尼替尼〖CAS号〗341031-54-7（苹果酸盐）；557795-19-4（游离碱）〖曾用代号〗SU-11248（苹果酸盐）〖作用类别〗激酶抑制剂类抗肿瘤药〖化学名〗(Z)-N-(2-(二乙基氨基)乙基)-5-((5-氟-2-氧代吲哚-3-亚基)甲基)-2,4-二甲基-1H-吡咯-3-羧酰胺苹果酸盐〖化学结构式〗专利信息年度销售情况（亿美元，信息来源：辉瑞公司年度财务报告及SEC报表）Tykerb药物基本信息〖NDA申请人〗Smithkline Beecham〖NDA原始批准日期〗2007年03月13日〖剂型/规格〗片剂/250mg；〖适应证〗1250mg QD+卡培他滨治疗肿瘤过度表达HER2且使用过包括蒽环类抗生素、紫杉烷类抗生素曲妥珠单抗在内的抗肿瘤药物治疗的晚期或转移性乳腺癌；1500 QD+来曲唑治疗HER2过度表达且需要进行激素治疗的绝经后妇女的激素受体阳性的转移性乳腺癌活性成分信息〖USAN名称〗Lapatinib ditosylate （monohydrate），拉帕替尼二（对甲基苯磺酸）盐（单水合物）〖CAS号〗388082-78-8〖曾用代号〗〖作用类别〗激酶抑制剂类抗肿瘤药；〖化学名〗N-[3-氯-4-[(3-氟苯基)甲氧基]苯基]-6-[5[[[2-(甲磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹啉胺二（对甲基苯磺酸）盐单水合物〖理化性质〗黄色固体，25℃下于水中的溶解度为0.007mg/mL，于0.1N HCl中的溶解度为0.001mg/mL〖化学结构式〗专利信息年度销售情况（亿英磅）Tasigna药物基本信息〖NDA申请人〗诺华制药〖NDA原始批准日期〗2007.10.29〖剂型/规格〗片剂/200mg（按游离碱计）〖适应证〗300mg BID用于于慢性期治疗新近确认成年患者的费城染色体阳性慢性髓样白血病；400mg BID用于于慢性期或急性期治疗成年患者对包括伊马替尼在内的先前治疗方法耐药或不耐受的费城染色体阳性慢性髓样白血病。

非药用类麻醉药品和精神药品管制品种目录（2015年版）
序号 1 2 3 4 5 6 7 8 9 10 11
中文名 N-(2-甲氧基苄基)-2-(2,5-二甲氧基-4-溴苯基)乙胺 2,5-二甲氧基-4-氯苯乙胺 N-(2-甲氧基苄基)-2-(2,5-二甲氧基-4-氯苯基)乙胺 2,5-二甲氧基-4-甲基苯乙胺 N-(2-甲氧基苄基)-2-(2,5-二甲氧基-4-甲基苯基)乙胺 2,5-二甲氧基-4-乙基苯乙胺 N-(2-甲氧基苄基)-2-(2,5-二甲氧基-4-碘苯基)乙胺 2,5-二甲氧基-4-丙基苯乙胺 2,5-二甲氧基-4-乙硫基苯乙胺 2,5-二甲氧基-4-异丙基硫基苯乙胺 2,5-二甲氧基-4-丙硫基苯乙胺
12 2-氟苯丙胺 13 2-氟甲基苯丙胺 14 1-(2-苯并呋喃基)-N-甲基-2-丙胺 15 3-氟苯丙胺 16 3-氟甲基苯丙胺 17 4-氯苯丙胺 18 4-氟苯丙胺 19 4-氟甲基苯丙胺 20 1-[5-(2,3-二氢苯并呋喃基)]-2-丙胺 21 1-(5-苯并呋喃基)-N-甲基-2-丙胺 22 6-溴-3,4-亚甲二氧基甲基苯丙胺 23 6-氯-3,4-亚甲二氧基甲基苯丙胺 24 1-(2,5-二甲氧基-4-氯苯基)-2-丙胺 25 1-(2-噻吩基)-N-甲基-2-丙胺 26 N-(1-氨甲酰基-2-甲基丙基)-1-(5-氟戊基)吲哚-3-甲酰胺 27 N-(1-氨甲酰基-2-甲基丙基)-1-(5-氟戊基)吲唑-3-甲酰胺 28 N-(1-氨甲酰基-2,2-二甲基丙基)-1-(5-氟戊基)吲哚-3-甲酰胺 29 N-(1-甲氧基羰基-2-甲基丙基)-1-(5-氟戊基)吲唑-3-甲酰胺 30 N-(1-金刚烷基)-1-(5-氟戊基)吲唑-3-甲酰胺 31 1-(5-氟戊基)吲哚-3-甲酸-8-喹啉酯 32 1-(5-氟戊基)-3-(2,2,3,3-四甲基环丙甲酰基)吲哚 33 1-[2-(N-吗啉基)乙基]-3-(2,2,3,3-四甲基环丙甲酰基)吲哚 34 1-(4-四氢吡喃基甲基)-3-(2,2,3,3-四甲基环丙甲酰基)吲哚 35 N-(1-氨甲酰基-2-甲基丙基)-1-(环己基甲基)吲唑-3-甲酰胺 36 N-(1-氨甲酰基-2-甲基丙基)-1-(4-氟苄基)吲唑-3-甲酰胺 37 N-(1-氨甲酰基-2-甲基丙基)-1-戊基吲唑-3-甲酰胺 38 N-(1-氨甲酰基-2,2-二甲基丙基)-1-戊基吲哚-3-甲酰胺 39 N-(1-氨甲酰基-2,2-二甲基丙基)-1-戊基吲唑-3-甲酰胺 40 1-[(N-甲基-2-哌啶基)甲基]-3-(1-萘甲酰基)吲哚 41 1-[(N-甲基-2-哌啶基)甲基]-3-(1-金刚烷基甲酰基)吲哚 42 1-[(N-甲基-2-哌啶基)甲基]-3-(2-碘苯甲酰基)吲哚 43 N-(1-金刚烷基)-1-戊基吲哚-3-甲酰胺 44 N-(1-金刚烷基)-1-戊基吲唑-3-甲酰胺 45 1-(1-萘甲酰基)-4-戊氧基萘 46 N-(1-甲基-1-苯基乙基)-1-(4-四氢吡喃基甲基)吲唑-3-甲酰胺 47 1-(5-氟戊基)-3-(4-乙基-1-萘甲酰基)吲哚 48 1-(4-氟苄基)-3-(1-萘甲酰基)吲哚 49 1-(4-氟苄基)吲哚-3-甲酸-8-喹啉酯 50 2-甲基-1-戊基-3-(1-萘甲酰基)吲哚 51 2-甲基-1-丙基-3-(1-萘甲酰基)吲哚 52 1-己基-3-(1-萘甲酰基)吲哚 53 1-戊基-3-(4-甲氧基-1-萘甲酰基)吲哚 54 1-戊基-3-(4-甲基-1-萘甲酰基)吲哚 55 1-戊基-3-(2-氯苯乙酰基)吲哚 56 1-戊基-3-(4-乙基-1-萘甲酰基)吲哚 57 1-戊基-2-(2-甲基苯基)-4-(1-萘甲酰基)吡咯 58 1-(5-氟戊基)-3-(4-甲基-1-萘甲酰基)吲哚 59 N-(1-甲氧基羰基-2,2-二甲基丙基)-1-(环己基甲基)吲哚-3-甲酰胺 60 N-(1-甲氧基羰基-2,2-二甲基丙基)-1-(4-氟苄基)吲唑-3-甲酰胺 61 1-戊基吲哚-3-甲酸-8-喹啉酯 62 N-(1-氨甲酰基-2-苯基乙基)-1-(5-氟戊基)吲唑-3-甲酰胺

甲磺酸萘莫司他中有机溶剂残留的测定目的建立气相色谱法测定甲磺酸萘莫司他中有机溶剂残留量。

方法在EC-1000（30 m×0.54 mm×1.2 μm）毛细管柱上采用程序升温法，载气为氮气，汽化室温度200 ℃，检测器温度220 ℃，以二氧六環为内标，内标法测定甲磺酸萘莫司他中残留的甲醇、丙酮、吡啶、N，N-二甲基甲酰胺。

结果在本研究色谱条件下，各溶剂及内标均能得到良好的分离度，空白无干扰；在所考察的浓度范围内线性良好，相关系数均在0.999 6以上，回收率96.7%～102.0%，检测限0.15～2.8 μg/mL。

结论试验建立的色谱方法简便、准确，灵敏度高，适合甲磺酸萘莫司他机溶剂残留量的检测。

[Abstract] Objective To establish a gas chromatography method for the determination of residual solvents in nafamostat mesilate. Methods The residual solvents in nafamostat mesilate were separated by EC-1000 capillary column（30 m×0.54 mm×1.2 μm）using programmed column temperature.N2 was used as carrier gas.and the temperature of injector and detector were 200℃and 220℃respectively.The residue of acetone,menthanol,pyridine and N,N-dimethylformamide in nafamostat mesilate were quantified with 1,4-dioxaneas internal standard. Results The solvents and internal standard were seperated completely,and blank showed no interference.The calibration curve of each solvent showed a good linear relationship(r≥0.9996).The average recovery was in the range of 97.6%～102.0%.The detection limit of acetone,methanol, pyridine and N,N-dimethylformamide were0.15～2.8 μg/mL. Conclusion The established method was simple，accurate and sensitive.It can be used for the determination of residual solvents in nafamostat mesilate.[Key words] Nafamostat mesilate;Residual solvents;Gas chromatography甲磺酸萘莫司他(nafamostat mesilate)，化学名为6-脒基-2-萘基-4-胍基苯甲酸酯二甲磺酸盐，是Japan Tobacco公司研发的非肽类蛋白酶抑制剂[1]，临床用于治疗急性胰腺炎[1-4]。